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ABSTRACT 
USE OF TEXT DATA IN IDENTIFYING AND PRIORITIZING POTENTIAL DRUG 
REPOSITIONING CANDIDATES 
 
by 
Majid Rastegar-Mojarad 
 
The University of Wisconsin-Milwaukee, 2019 
Under the Supervision of Professor Susan McRoy 
New drug development costs between 500 million and 2 billion dollars and takes 10-15 years, with 
a success rate of less than 10%. Drug repurposing (defined as discovering new indications for 
existing drugs) could play a significant role in drug development, especially considering the 
declining success rates of developing novel drugs. In the period 2007-2009, drug repurposing led 
to the launching of 30-40% of new drugs. Typically, new indications for existing medications are 
identified by accident. However, new technologies and a large number of available resources 
enable the development of systematic approaches to identify and validate drug-repurposing 
candidates with significantly lower cost. A variety of resources have been utilized to identify novel 
drug repurposing candidates such as biomedical literature, clinical notes, and genetic data. In this 
dissertation, we focused on using text data in identifying and prioritizing drug repositioning 
candidates and conducted five studies.  
In the first study, we aimed to assess the feasibility of using patient reviews from social media to 
identify potential candidates for drug repurposing. We retrieved patient reviews of 180 
medications from an online forum, WebMD. Using dictionary-based and machine learning 
approaches, we identified disease names in the reviews. Several publicly available resources were 
used to exclude comments containing known indications and adverse drug effects. After manually 
reviewing some of the remaining comments, we implemented a rule-based system to identify 
 iii 
beneficial effects. The dictionary-based system and machine learning system identified 2178 and 
6171 disease names respectively in 64,616 patient comments. We provided a list of 10 common 
patterns that patients used to report any beneficial effects or uses of medication. After manually 
reviewing the comments tagged by our rule-based system, we identified five potential drug 
repurposing candidates. To our knowledge, this was the first study to consider using social media 
data to identify drug-repurposing candidates. We found that even a rule-based system, with a 
limited number of rules, could identify beneficial effect mentions in the comments of patients. Our 
preliminary study shows that social media has the potential to be used in drug repurposing. 
In the second study, we investigated the significance of extracting information from multiple 
sentences specifically in the context of drug-disease relation discovery. We used multiple 
resources such as Semantic Medline, a literature-based resource, and Medline search (for filtering 
spurious results) and inferred 8,772 potential drug-disease pairs. Our analysis revealed that 6,450 
(73.5%) of the 8,772 potential drug-disease relations did not occur in a single sentence. Moreover, 
only 537 of the drug-disease pairs matched the curated gold standard in the Comparative 
Toxicogenomics Database (CTD), a trusted resource for drug-disease relations. Among the 537, 
nearly 75% (407) of the drug-disease pairs occur in multiple sentences. Our analysis revealed that 
the drug-disease pairs inferred from Semantic Medline or retrieved from CTD could be extracted 
from multiple sentences in the literature. This highlights the significance of the need for discourse-
level analysis in extracting the relations from biomedical literature.  
In the third and fourth study, we focused on prioritizing drug repositioning candidates extracted 
from biomedical literature which we refer to as Literature-Based Discovery (LBD). In the third 
study, we used drug-gene and gene-disease semantic predications extracted from Medline abstracts 
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to generate a list of potential drug-disease pairs. We further ranked the generated pairs, by 
assigning scores based on the predicates that qualify drug-gene and gene-disease relationships. On 
comparing the top-ranked drug-disease pairs against the Comparative Toxicogenomics Database, 
we found that a significant percentage of top-ranked pairs appeared in CTD. Co-occurrence of 
these high-ranked pairs in Medline abstracts is then used to improve the rankings of the inferred 
drug-disease relations. Finally, manual evaluation of the top-ten pairs ranked by our approach 
revealed that nine of them have good potential for biological significance based on expert 
judgment. 
In the fourth study, we proposed a method, utilizing information surrounding causal findings, to 
prioritize discoveries generated by LBD systems. We focused on discovering drug-disease 
relations, which have the potential to identify drug repositioning candidates or adverse drug 
reactions. Our LBD system used drug-gene and gene-disease semantic predication in SemMedDB 
as causal findings and Swanson’s ABC model to generate potential drug-disease relations. Using 
sentences, as a source of causal findings, our ranking method trained a binary classifier to classify 
generated drug-disease relations into desired classes. We trained and tested our classifier for three 
different purposes: a) drug repositioning b) adverse drug-event detection and c) drug-disease 
relation detection. The classifier obtained 0.78, 0.86, and 0.83 F-measures respectively for these 
tasks. The number of causal findings of each hypothesis, which were classified as positive by the 
classifier, is the main metric for ranking hypotheses in the proposed method. To evaluate the 
ranking method, we counted and compared the number of true relations in the top 100 pairs, ranked 
by our method and one of the previous methods. Out of 181 true relations in the test dataset, the 
proposed method ranked 20 of them in the top 100 relations while this number was 13 for the other 
method. 
 v 
In the last study, we used biomedical literature and clinical trials in ranking potential drug 
repositioning candidates identified by Phenome-Wide Association Studies (PheWAS). Unlike 
previous approaches, in this study, we did not limit our method to LBD. First, we generated a list 
of potential drug repositioning candidates using PheWAS. We retrieved 212,851 gene-disease 
associations from PheWAS catalog and 14,169 gene-drug relationships from DrugBank. 
Following Swanson’s model, we generated 52,966 potential drug repositioning candidates. Then, 
we developed an information retrieval system to retrieve any evidence of those candidates co-
occurring in the biomedical literature and clinical trials. We identified nearly 14,800 drug-disease 
pairs with some evidence of support. In addition, we identified more than 38,000 novel candidates 
for re-purposing, encompassing hundreds of different disease states and over 1,000 individual 
medications. We anticipate that these results will be highly useful for hypothesis generation in the 
field of drug repurposing. 
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Chapter 1: Introduction 
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1.1 Drug repositioning 
 
Drug development is an expensive and time-consuming process. Developing a new drug costs 
$500 million to $2 billion and takes 10-15 years [1]. In average, developing an oncology drug 
takes 13 years and could cost 1.8 billion [2]. The enormous cost and lengthy process of drug 
development underline the need for an alternative approach. A well-known approach to reducing 
the cost and time of new drug development is drug repositioning [3] which is also known as drug 
repurposing, re-profiling, re-tasking or therapeutic switching [4], [5] 1. Drug repositioning is the 
process of identifying new indications for existing or failed drugs. Figure 1 shows time-lines for 
drug discovery and drug repositioning process and highlights their differences [4].  
  
 
 
 
 
 
Drug repositioning could play a significant role in the drug development process. Since 
repositioning relies on previously approved drugs that already passed multiple toxicity tests in the 
first phase (Figure 1-a) of drug development process and their toxicity profiles are already known 
[2], drug repositioning candidates tend to be ready for clinical trials quickly and be reviewed by 
Food and Drug Administration (FDA) faster [5]. Drug repositioning can decrease the traditional 
                                               
1 Shameer et al. [4] provided an overview of definition for drug repositioning and related methods which repurpose 
pharmaceutical compounds. 
a) 
Target 
screen 
Tool 
compound 
Candidate 
compound 
Preclinical 
development 
Clinical 
development 
Therapy 
Phase one 
b) 
Clinical or 
marketed 
drug 
Clinical or 
computational 
repositioning 
Clinical 
development Therapy 
Figure 1: Comparing timelines of traditional drug discovery and drug repositioning [4] a) timeline in 
traditional drug discovery process b) timeline of drug repositioning 
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timeline from 10-17 years to only 3-12 years [5]. The significance of drug repositioning would be 
more tangible knowing a small percentage of proposed drugs are able to pass the first phase 
successfully. In average less than 10% [6] of proposed drugs pass the first phase. This rate for 
oncology drugs is only 5% [2]. This low rate of success emphasizes the importance of drug 
repositioning in reducing the cost and risk of drug development. There have been many efforts on 
using repositioning which led to many successful discoveries.  
1.2 Successful drug repositioning discoveries 
One of the earliest drug repositioning cases is the use of reticulose for post-radiation effects in the 
1950s [7], [8], [4]. Later in the 1980s, anti-malarial drugs were suggested as potential repurposing 
candidates for rheumatoid arthritis and connective tissue disease [9]–[11]. One famous example 
of drug repositioning is Pfizer’s sildenafil (Viagra) which was repositioned from angina treatment 
to erectile dysfunction treatment in men in 1998 [12] and has recently been studied as a possible 
treatment for Age-related Macular Degeneration [13]. Thalidomide is another example of drug 
repositioning. Thalidomide first introduced as a sedative hypnotic [14] and then it was withdrawn 
because of severe side-effects. Later, Thalidomide was re-introduced as an anti-cancer agent and 
used for erythema nodosum leprosum and HIV wasting syndrome. In recent clinical trials, 
Duloxetine, a medication for depression, was found to be effective in the treatment of stress urinary 
incontinence in women [15]. Overall, from 2007-2009, approximately 30-40% of newly approved 
drugs were repurposed medications [16]. 
1.3 Drug repositioning approaches 
Typically, a new indication for an available drug is identified only by chance. However, new data 
analytic technologies and a large number of available resources now enable the development of 
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systematic approaches to identify and assess drug repositioning candidates with considerably 
lower costs. Drug repositioning has been exhaustively studied, and various approaches have been 
used [16]–[18] to identify novel drug repositioning candidates. They have used clinical data [19], 
[20], genetic information [21]–[23], scientific literature [24]–[26], pathway information [27], 
chemical structure similarity [28], and databases of clinical side effects [29]. 
Several meta-analyses of drug repositioning allow us to categorize the different approaches. 
Dudley et. al. [30] reviewed computational methods for drug repositioning and categorized the 
methods into two classes: drug-based and disease-based, based on whether drug or disease 
perspective initiates the discovery. Wei et. al. [24] categorized the computational drug 
repositioning methods into literature-based and ontology-based. Grau and Serbedzija [17] named 
two types of drug repositioning: (1) identification of off-target drug actions and (2) identification 
of relevance of a known drug target to a new disease. In general, drug repositioning methods can 
be drug, disease or target oriented and can be further sub-classified into target-based, knowledge-
based, signature-based, network-based and targeted-mechanism-based approaches [16], [31]. 
From an informatics perspective, we can categorize repositioning methods based on resources 
utilized to extract drug repositioning discoveries. These resources include scientific literature, 
clinical data, social media, and biological resources. The compound database PubChem [32] has 
been used in several drug-repurposing studies [33]. Hoehndorf et al [34] implemented a system 
that inferred novel associations between drugs and diseases by linking drug-gene associations in 
the PharmGKB database to phenotype studies and animal models of disease. Moriaud et al [35] 
presented a computational method that mined the Protein Data Bank [36] to identify drug 
repositioning candidates. Several studies [24], [25], [34], [35], [37], [38] considered literature 
mining for drug repurposing; this approach has been comprehensively reviewed elsewhere [39], 
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[40]. Another valuable resource is social media. Although patients mostly use medically oriented 
social media to describe adverse events associated with drugs [41], [42], their experiences may 
help others to conceive of new indications for existing medications if their descriptions also 
include beneficial effects. A well-known example is Zolpidem, an insomnia medication that, 
through social media and patient reviews, was subsequently used for brain injury [43]. Leaman at 
el [44] identified 157 beneficial effects from 3600 patient posts that could lead to drug repurposing. 
The accuracy of these reported beneficial effects in social media requires additional confirmation, 
but considering the value of drug repurposing and the huge amount of available social media data, 
it is worthwhile to study this type of information and investigate the possibility of identifying 
potential drug-repurposing candidates. 
In the next chapter, we discuss related works in more detail. 
1.4 Our contributions 
This dissertation focuses on the use of text data in the drug repositioning process. We identify and 
assess challenges and opportunities in using text data in two main tasks of drug repositioning:  
1) identifying potential candidates for drug repositioning (DR) and  
2) validating (or prioritizing) the potential candidates.  
The contributions in this dissertation consist of the following: 
• Assessing the feasibility of using social media data in identifying potential drug repurposing 
candidates. Our hypothesis is that this imperfect resource could support drug repurposing by 
helping to identify unknown beneficial effects of drugs. This requires 1) gathering users’ 
comments in social media 2) identifying mentions of medication names (including generic names, 
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synonyms, and brand names), instances of actual (rather than hypothetical) uses, and contrasting 
these uses with the original indications found in published sources such as DrugBank.) We 
examine two named entity recognition methods: 1) dictionary-based and 2) machine learning. We 
develop a rule-based system to tag sentences with potential uses for drug repositioning. To evaluate 
our system, we manually review the sentences which were tagged as positive to assess the 
possibility of the potential drug repositioning candidates to be a true finding. As there is not any 
gold standard for this task, we are not able to evaluate our system using more formal common 
metrics such as precision, recall, and F-measure. 
• Comparing the number of relations that can be extracted from single sentences versus multiple 
sentences. Our goal is to assess the number of relations which relation extraction systems might 
be missing if they just focus on sentence-level analysis and to quantify the need for going beyond 
sentence-level extraction and implementing a relation extraction system capable of both sentence-
level and discourse-level extraction. This study focusses on drug-disease relation extraction as a 
case study. It uses two available resources, Semantic Medline and Comparative Toxicogenomics 
Database (CTD), to infer drug-disease relations and then compare the coverage of these relations 
in sentence level extraction versus discourse level extraction. This study provides a means to 
compare the potential importance of considering both a) single sentences and b) multiple sentences 
in relation extraction systems for the task of identifying drug repositioning candidates from text 
data. 
• Evaluating the effectiveness of two new methods to prioritize potential drug repositioning 
candidates identified by literature-based discovery (LBD) systems. In the first method, we consider 
LBD systems which use semantic predications to generate a list of potential candidates. In this 
study, we use predicates in semantic predications as the main metric to rank the candidates. We 
 7 
assess our method by comparing it against curated databases such as CTD and expert judgment. 
In the second method, we train a binary classifier, using text surrounding the discoveries, to 
classify the discoveries into desired classes. To evaluate the performance of these classifiers, we 
calculate precision, recall, and F-measure. 
• Evaluating the use of published biomedical literature and clinical trials in ranking potential DR 
candidates identified by Phenome-Wide Association Studies (PheWAS) [45]. We first generate a 
list of potential DR candidates using PheWAS. Then, we develop an information retrieval system 
to retrieve any evidence of those candidates appearing in the biomedical literature and clinical 
trials. We use this information to prioritize our discoveries. Like previous methods, we ask an 
expert to provide judgments to evaluate the performance of our ranking method. 
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2.1 Introduction 
In this chapter, we review related works focusing on identifying potential DR candidates using 
biomedical literature, social media and then the current studies on validation of potential DR 
candidates. 
2.1.1 Use of biomedical literature in drug repositioning 
In the past decade, advances in high throughput biotechnology have shifted biomedical research 
from individual genes and proteins to entire biological systems. To make sense of the large-scale 
data sets being generated, researchers must increasingly be able to connect with research fields 
outside of their core competence. In addition, researchers must interpret massive amounts of 
existing knowledge while keeping up with the latest developments. One way researchers cope with 
the rapid growth of scientific knowledge is to specialize, which leads to a fragmentation of the 
scientific literature. This specialization or fragmentation of literature is a growing problem in 
science, particularly in biomedicine. Researchers tend to correspond more within their fragments 
than with the field’s broader community, promoting poor communication between specialties [46]. 
This is evidenced within the citations of such literature as authors tend to heavily cite those within 
their narrow specialties. Interesting and useful connections may go unnoticed for decades. This 
situation has created both the need and opportunity for developing sophisticated computer-
supported methodologies to complement classical information processing techniques such as 
information retrieval [26].  
Text mining can help bridge the gaps among subdisciplines by extracting new findings from the 
literature and presenting them to researchers based on their research interest, without requiring 
them to spend hours manually reading through new publications. There are systems, which go 
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beyond that and after extracting findings from the literature, use the findings to suggest and assess 
new hypotheses [47]. These systems support a process called Literature-Based Discovery (LBD) 
[26]. LBD strives to find novel connections or correlations between concepts by using scientific 
literature. LBD systems usually are comprised of the following steps: 
1) Extracting findings (especially causal findings) from the scientific literature  
2) Generating new hypotheses 
3) Prioritizing and ranking the hypotheses 
The first step usually carries out information extraction using natural language processing and 
machine-learning techniques. To generate new hypotheses, Swanson’s ABC model [48] is a 
common and well-known approach. The ABC model, which we explain later, cross-references 
findings extracted from different articles and hypothesizes new findings. Validating these 
hypotheses, manually by experts, is expensive and time-consuming which makes the role of the 
third step within LBD systems extremely significant. 
Similar to other domains, in the biomedical domain, a large pool of scientific literature is available 
that has been utilized by researchers to design and implement a variety of LBD systems which has 
led to valuable new discoveries [49]. In 1986, Don Swanson [50] introduced LBD and 
hypothesized that fish oil may have beneficial effects in patients with Raynaud’s syndrome based 
on the following findings that he concluded from two separate groups of literature: 
1) Raynaud’s syndrome (A) patients have blood viscosity (B) disorder  
2) Fish oil (C) can reduce blood viscosity (B). 
Later the hypothesis was verified by clinical trials. This model is now known as Swanson ABC 
model. Swanson implemented the model in a software system, called ArrowSmith [51], to 
automate the hypothesis generation process. As the above example illustrates, the model contains 
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three entities/concepts, A as starting, B as linking, and C as target concept [52]. The discovery 
process starts with mining associations between A - B and B - C from literature, then by combining 
the associations with the same linking concept, a list of potential A-C associations is created. If 
there is not any prior mention about a relation between A and C in literature, then a hypothesis of 
association between A and C can be formulated which can be confirmed or rejected through human 
judgment, laboratory methods or clinical investigations. The ABC model can be implemented in 
two discovery manners, open and closed. In closed-discovery, the starting and target concepts are 
determined by the user and the LBD system only identifies linking concepts. In the open-discovery 
approach, the starting and target entities are not limited to any specific concept. This approach 
usually generates a long list of potential relations. As mentioned, to reject or confirm each of these 
relations, each candidate should be evaluated through clinical trials and laboratory experiments, 
which are expensive and time consuming. LBD systems can facilitate and accelerate this step by 
providing initial validation, using computational methods and existing knowledge, and narrowing 
down the list to a more reasonable number of candidates. Otherwise, it is not cost effective for 
other researchers or scientists to investigate the numerous numbers of candidates provided by 
open-discovery methods. 
There have been several LBDs implemented to generate hypotheses by following Swanson’s 
paradigm, which has led to interesting and useful discoveries [53]. One of the most desirable 
findings in the biomedical domain is drug-disease relation which could shed light on side effects 
or new indications for an existing drug [54]. The latter one is known as drug repositioning which 
we introduced previously and has been receiving much attention from pharmaceutical companies 
and researchers. New uses connecting indomethacin and Alzheimer’s disease [55], somatomedin 
c and arginine [56], anandamide and gastric cancer [57], psychiatric and somatic diseases [58], 
 12 
hypogonadism and diminished sleep quality [59], NF-kappaB and autism [60] are some of these 
findings. LBD can be utilized to discover any type of relation such as disease candidate genes [61], 
drug-drug interaction [62], drug mechanism [63], adverse drug reaction [64].  
All LBD systems mentioned above have utilized a similar paradigm, but their approaches for 
identifying starting, linking, and target concepts in text and extracting relationships between them 
vary. To identify desired concepts in literature, usually LBDs rely on named entity recognition 
systems [65] or medical subject heading (MeSH), terms assigned by experts to Medline abstracts 
[66] that describe the content of the associated abstract. BITOLA [61] is one of the LBD systems 
that uses assigned MeSH terms to each Medline abstract as concepts. After identifying concepts, 
LBD can be used to extract the relationship between the concepts (causal associations). Some 
common methods are: co-occurrence [61], association rules [67], term frequency–inverse 
document frequency [68], Z-Score [69], and mutual information [70]. Other approaches are 
available to identify associations between concepts and terms that do not co-occur with one another 
in the biomedical literature [71][72]–[74]. Yetisgen-Yildiz and Pratt [52] survey these approaches 
and Andronis et al. [54] reviews literature mining systems which have been applied to identifying 
potential drug repurposing candidates. 
Another approach for generating causal associations is using semantic predication [75]. A semantic 
predication is a “subject – predicate – object” triple extracted from the literature. For example, in 
the domain of drug repositioning, Subject and object are biomedical concepts from the UMLS 
Metathesaurus [76] and predicate is a relation from the UMLS Semantic Network such as: affects, 
causes, associated with, treats, etc. Semantic predications for the biomedical domain have been 
extracted by a rule-based system called SemRep [77] and stored in a relational database called, 
SemMedDB [78]. The latest version of this database contains more than 84 million predications, 
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extracted from 25 million PubMed abstracts. This resource has been used in several studies to 
facilitate knowledge discovery [79]–[81]. Hristovski et al. [75] proposed a method to use semantic 
predication to enhance their LBD system, BITOLA. They concluded that using semantic 
predications instead of co-occurrences generates a smaller number of false positive discoveries 
and provides an explanation to support the findings. Ahlers et al [63] used semantic predications 
in a closed-LBD system to discover connections between antipsychotic agents and cancer. Cohen 
et al. [71] proposed using hyper dimensional computing in a LBD system based on semantic 
predications. They suggested a method, called predication-based semantic indexing, to build a 
sequence of semantic predications, which ultimately associate a drug to a disease as a novel 
therapy. Cameron et al [53] proposed an automatic subgraph creation method, based on semantic 
predications, to facilitate LBD. Workman and Stoddart [79] proposed using Semantic Medline as 
a source for building a decision support system for point of care. The Natural Language Processing 
Group at the Mayo clinic integrated semantic predications into a system, called Ask Mayo Expert 
(AME), to retrieve the most relevant literature to support the evidence-based clinical decision 
making process at point of care [80]. 
2.1.2 Use of Social media in Drug Repositioning 
Social media provides a platform for patients to share their experiences with illnesses, medications, 
and also medical centers [82]. Patient posts, usually written in an informal language, contain 
hidden and valuable information. Owing to the massive amount of data derived from social media, 
computerized systems are needed to analyze and extract useful information from patient 
experience. Unlike scientific literature, these comments are usually written by non-expert users 
who do not have any obligation to follow proper grammar in their comments or report observations 
accurately. These differences make mining social media more complicated and challenging 
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compared to scientific literature. Nevertheless, there have been several attempts to extract 
knowledge from social media. Leaman et al [44] examined comments posted in a medical forum 
to identify reported adverse drug events. After manually annotating a corpus of patient posts, they 
used natural language processing methods to develop a system that extracted adverse drug 
reactions from the text. Chee et al [83] studied patient posts on Health and Wellness Yahoo! groups 
and applied common natural language processing methods to predict adverse drug events and 
identify medications that might require further scrutiny by the Food and Drug Administration. 
Freifeld et al [84] evaluated the correlation between adverse drug events reported in Twitter (where 
statements are limited to 140 characters) and spontaneous reports received by a regulatory agency. 
Rastegar et al [85] implemented a binary classifier to identify adverse drug reactions in tweets. 
Sharif et al [86] proposed a sentiment classification framework to detect adverse drug reactions in 
medical blogs and forums. Recently, Karimi et al [87] provided a corpus of 1321 medical forum 
posts on patient-reported adverse drug events, which allows researchers to develop and evaluate 
pharmacovigilance systems.  
Although patients mostly use medically oriented social media to describe adverse events 
associated with drugs [41], [42] , their experiences may help others to conceive of new indications 
for existing medications if their descriptions also include beneficial effects. A well-known example 
is Zolpidem, an insomnia medication that, through social media and patient reviews, was 
subsequently used for brain injury [43]. Leaman at el [44] identified 157 beneficial effects, in 3600 
patient posts that could lead to drug repurposing. The accuracy of these reported beneficial effects 
in social media may be questionable, but considering the value of drug repurposing and the huge 
amount of available social media data, it is worthwhile to study this type of information and 
investigate the possibility of identifying potential drug-repurposing candidates [88].  
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2.1.3 Validation and prioritizing potential drug repositioning candidates 
As mentioned in the description of LBD above, one challenging and expensive task after 
identifying potential drug repurposing candidates is validation. The discoveries can be confirmed 
or rejected through human judgment, laboratory methods, or clinical investigations. The validation 
could be facilitated with automated ranking and prioritizing of the potential candidates. There have 
been several studies which proposed ranking algorithms, mostly as part of LBD systems. However 
there have been several attempts to propose effective ranking methods [69], [70], [89] but this area 
has been largely unexplored. Wren proposed an algorithm called average minimum weight (AMV) 
[70]. The algorithm calculates a weight for each potential discovery (A-C) based on the strength 
of A-B and B-C relations. The strength of each relation is calculated based on mutual information. 
The algorithm considers all possible B concepts that have a relation with A and C in the calculation. 
Another approach to rank the findings is proposed by Yetisgen-Yildiz and Pratt [69], [90]. They 
used the number of B concepts that link A to C as the indication of a strong correlation. The 
method, which called Linking Term Count with Average Minimum Weight (LTC-AMW), uses 
AMV in case of a tie. Swanson et al. [89] introduced a measure to rank the discoveries based on 
MeSH terms in literature called Literature Cohesiveness. AMV and LTC-AMV are generic and 
can be used in different LBD systems, but these algorithms do not consider semantic predicates in 
their calculation. 
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3.1 Introduction 
Social media provides a platform for patients to share their experiences with illnesses, medications, 
and medical centers [82], [91]. Patient posts, usually written in an informal language, contain 
hidden and valuable information. Owing to the massive amount of data derivable from social 
media, computerized systems are needed to analyze and extract useful information from the 
patient’s perspective. Unlike edited scientific literature, these comments are usually written by 
non-expert users who may not follow proper grammar in their comments or report complete or 
accurate observations. These differences make mining social media more challenging compared 
to scientific literature. Nevertheless, there have been several successful attempts to extract 
knowledge from social media. Leaman et al [44] examined comments posted in a medical forum 
to identify reported adverse drug events. After manually annotating a corpus of patient posts, they 
used natural language processing methods to develop a system that extracted adverse drug 
reactions from the text. Chee et al [83] studied patient posts on Health and Wellness Yahoo! groups 
and applied common natural language processing methods to predict adverse drug events and 
identify medications that might require further scrutiny by the Food and Drug Administration. 
Freifeld et al [84] evaluated the correlation between adverse drug events reported in Twitter (where 
statements are limited to 140 characters) and spontaneous reports received by a regulatory agency. 
Rastegar et al [85] implemented a binary classifier to identify adverse drug reactions in tweets. 
Sharif et al [86] proposed a sentiment classification framework to detect adverse drug reactions in 
medical blogs and forums. Recently, Karimi et al [87] provided a corpus of 1321 medical forum 
posts on patient-reported adverse drug events, which allows researchers to develop and evaluate 
pharmacovigilance systems. 
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Although patients have mostly used medically oriented social media to describe adverse events 
associated with drugs [41], [42], patients also sometimes report beneficial effects and their 
experiences may also help others to conceive of new indications for existing medications. A well-
known example is Zolpidem, an insomnia medication that was subsequently used for brain injury 
[43]. The miracle of this medication discovered in 1994, when a patient who suffered severe brain 
injuries and went to coma, started to take Zolpidem as a sedative but it brought him back to life. 
Since then, Zolpidem has been waking up several brain-injured patients from a vegetative state. 
Leaman at el [44] identified 157 beneficial effects, in 3600 patient posts that could lead to drug 
repurposing. These reported beneficial effects in social media may not always be completely 
accurate (and possibly vulnerable to a placebo effect [44]), but considering the potential value of 
drug repurposing and huge amount of available social media data, it is worthwhile to study this 
type of information and investigate the possibility of identifying potential drug-repurposing 
candidates. In this chapter, we consider the feasibility of using social media data in identifying 
potential drug repurposing candidates. Our hypothesis is that this imperfect resource can be used 
to identify candidates for drug repurposing by revealing new beneficial effects of medications 
taken by patients and reported in social media. We collect patient reviews of 180 medications in 
an online forum and then use common Named Entity Recognition approaches, we identify 
beneficial or side effects reported by patients for each drug. We utilize public resources to 
distinguish known side effects and beneficial effects from potentially new ones and then using a 
rule-based system separate side effects from beneficial effects. To evaluate our approach, we 
manually evaluate the finding. 
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3.2 Data Sources 
Data for this study is obtained from public resources to allow for replicability. We use four public 
resources: WebMD [92], DrugBank [93], SIDe Effect Resource (SIDER) [94], and Unified 
Medical Language System (UMLS) [76]. Below are brief descriptions of these resources and their 
uses in this research. 
WebMD is a collection of Web-based health-related services provided by a US corporation, that 
consistently ranks as the top US health publisher in the United States [92]. It includes a forum 
specifically for patients to share their experiences with medications. The comments are entered as 
free text, and the length of comments is not subject to a character or word count limit. WebMD 
[92] allows users to score three different aspects of the medication in their reviews: (1) 
effectiveness, (2) ease of use, and (3) satisfaction. WebMD provides some basic information about 
the users such as age, sex, and duration of treatment. Figure 2 shows a screenshot of a WebMD 
review page. The patient comments from WebMD were the main material used in this study. 
DrugBank is a bioinformatics and cheminformatics resource that provides drug information, such 
as indication, synonyms, gene target, drug interactions, and structure. This database can be used 
to identify the current indications of drugs and thus to identify mentions of potential new uses as 
distinct from the prior ones. 
SIDER, developed by Kuhn et al [94], contains information about 1430 marketed medications and 
5880 side effects (140,064 drug-side effect pairs) extracted from public documents and package 
inserts. The developers of SIDER retrieved adverse drug reaction and disease names from UMLS 
to generate a dictionary of side effects. One can use SIDER to identify known side effects of drugs 
mentioned in the comments. 
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UMLS [76] integrates medical terminology and coding standards to help researchers and 
developers create interoperable biomedical information systems. One can use UMLS resources to 
create a dictionary of disease names that might potentially be treated by repurposed drugs.  
 
Figure 2: A screenshot of WebMD web page which allows users to post a comment about a medication and rate it 
based on effectiveness, ease of use, and satisfaction. 
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3.3 Method 
3.3.1 Creating a Table of Medications 
In the first step, we create a table of medications frequently mentioned in social media, the 
approved indications of these medications, and known side effects. For the list of medications, we 
generate a list of the top 180 most frequently searched medications on WebMD. Through 
DrugBank, we collect known and approved indications related to those medications. To locate the 
drugs in DrugBank, we search drug names, synonyms and brand name entries. In the next step, a 
list of known side effects for each drug is retrieved from SIDER. Finally, we retrieve all user-
generated reviews posted in WebMD about these medications. (WebMD categorizes reviews for 
each medication, therefore distinguishing comments for each medication is a straightforward task 
and there is not any need to locate or identify drug names in the comments.) 
3.3.2 Identification of Medication Effects within Consumer Reviews 
We next identify beneficial or adverse effects within the posted reviews. Beneficial effects would 
be their impact on reducing some observed negative health condition, such as a rash. For 
simplicity, we refer to such negative conditions as “diseases” although they might be symptoms 
or observations related to a disease. Any mentions of disorders in the reviews are tagged by using 
two disease named entity recognition (NER) approaches. 
In the first approach, which can be considered a dictionary-based approach, a list of disease names 
from UMLS is retrieved and a string-matching technique applied to identify any of the diseases 
mentioned in the comments. The dictionary-based approach misses mentions that are either 
semantic or grammatical variants of standard forms, so for these, a second approach was employed. 
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The second approach uses MetaMap [95]. We evaluate these two approaches by comparing disease 
names identified by each for the top ten most reviewed medications.  
Since we are interested in newly reported uses, we discard reviews that contain only known adverse 
effects for related medication, using the table we created previously. We then manually review 
100 of the remaining comments to develop a list of textual patterns used to report beneficial effects 
or indications. Using the textual patterns, we implement a rule-based system to tag the reported 
beneficial effects within the comments. We report the frequency of each textual patterns in the 
comments, before and after removing side effects and any previously known indications. In the 
final step and as the evaluation, the comments that contained any of the textual patterns are 
manually reviewed. 
3.4 Results 
3.4.1 Statistics of the medication table 
The results of retrieving consumer generated posts for the top 180 most commonly searched drugs 
in WebMD (mean number of posts per drug was 358) yielded 64,616 separate posts. Within this 
set, Lisinopril (an angiotensin-converting enzyme inhibitor used to treat high blood pressure and 
heart failure) had the most comments (n=2931), whereas metoclopramide (used to treat gastric 
esophageal reflux disease) had the fewest comments (n=8). Table 1 shows the top 10 reviewed 
medications and includes the three most frequently named diseases in the respective comments. 
The dictionary created to capture all spelling variants of diseases provided in UMLS included 
239,227 entries for 86,839 unique diseases. 
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Table 1: Most reviewed medications in WebMD and most frequently named diseases in reviews. 
Drug name  Number of 
Reviews 
Number of Disease names Most frequent disease names 
Dictionary-
based 
MetaMap Dictionary-
based 
MetaMap 
Lisinopril 2931 288 1135 Itch Blood 
pressure 
High blood 
pressure 
Cough 
Rash Dry cough 
Hydrocodone-
acetaminophen 
2684 320 987 Arthritis Pain 
Itch Back pain 
Chronic pain Arthritis 
Phentermine 1931 207 860 Dry mouth Dry mouth 
Depression Weight loss 
Obese Blood 
pressure 
Cymbalta 1651 320 1063 Depression Depression 
Itch Anxiety 
Fibromyalgia Weight gain 
Lexapro 1609 269 864 Depression Depression 
Itch Weight gain 
Panic attack Anxiety 
Effexor 1568 290 943 Depression Depression 
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Drug name  Number of 
Reviews 
Number of Disease names Most frequent disease names 
Dictionary-
based 
MetaMap Dictionary-
based 
MetaMap 
Itch Dizziness 
Panic attack Anxiety 
Tramadol 1404 261 826 Arthritis Pain 
Fibromyalgia Back pain 
Migraine Dizziness 
Trazodone 1305 226 701 Depression Insomnia 
Dry mouth Depression 
Chronic 
insomnia 
Anxiety 
Topamax 1191 271 840 Migraine Migraine 
Gist Headaches 
Memory loss Tingling 
Percocet 1125 245 713 Itch Pain 
Chronic pain Abuse 
Arthritis Back pain 
 
 
The dictionary-based NER approach identified 2178 disease names in the comments, whereas 
MetaMap identified 6171 disease mentions. Table 2 shows the 10 most commonly named diseases 
in the comments (after disambiguated terms and variations of diseases were removed manually).  
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Table 2: Most frequently named diseases in reviews. 
Dictionary-based MetaMap 
Disease Count Disease Count 
Depression 5602 Pain 9990 
Itch 3594 Depression 4921 
Migraine 1610 Blood pressure 4016 
Dry mouth 1269 Weight gain 3778 
Infection 1218 Dizziness 3484 
Panic attack 1174 Anxiety 3323 
Rash 1086 Headache 2216 
Arthritis 905 Nausea 1977 
Fibromyalgia 850 Relief 1671 
Mood swing 730 Dry mouth 1279 
 
Of the 180 drugs, 164 (91.1%) were listed in DrugBank but only 74 (41.1%) were listed in SIDER. 
After filtering comments to remove text describing known indications and adverse drug events 
from the list of recognized disease names, the top three most frequently named “new” diseases 
from the text that remained are shown in Table 3 (note the overlap with Table 1). 
 26 
Table 3: Most-reviewed medications in WebMD and most frequently named diseases in the reviews after removing 
known indications and adverse drug events. 
Drug name  
Number of Disease names 
Most frequent new disease 
names 
Dictionary-
based 
MetaMap Dictionary-
based 
MetaMap 
Lisinopril 280 1124 Itch Blood 
pressure 
High blood 
pressure 
Cough 
Rash Dry cough 
Hydrocodone-
acetaminophen 
320 987 Arthritis Pain 
Itch Back pain 
Chronic pain Arthritis 
Phentermine 195 834 Depression Weight loss 
Obese Blood 
pressure 
High blood 
pressure 
Sleeping 
Cymbalta 320 1063 Depression Depression 
Itch Anxiety 
Fibromyalgia Weight gain 
Lexapro 269 864 Depression Depression 
Itch Weight gain 
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Drug name  
Number of Disease names 
Most frequent new disease 
names 
Dictionary-
based 
MetaMap Dictionary-
based 
MetaMap 
Panic attack Anxiety 
Effexor 290 943 Depression Depression 
Itch Dizziness 
Panic attack Anxiety 
Tramadol 200 670 Fibromyalgia Pain 
Chronic pain Back pain 
Migraine Headache 
Trazodone 196 609 Chronic 
insomnia 
Depression 
Migraine Anxiety 
Fibromyalgia Headache 
Topamax 271 840 Migraine Migraine 
Gist Headaches 
Memory loss Tingling 
Percocet 245 713 Itch Pain 
Chronic pain Abuse 
Arthritis Back pain 
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3.4.2 Statistics of Textual Patterns 
We identified 18 textual patterns used (or can be used) to report beneficial effects and then counted 
the frequency of them in the reports. The frequencies of the top ten most common are shown in 
Table 4.  
Table 4: Textual patterns to identify drug repositioning candidates. 
Pattern Count Example drugs and comments2 
I use * for 307 Methadone: I use this for diabetic neuopathy. works well with very 
little side effects. 
Percocet: I use this for M.S. pain 
Percocet: I use this med for peripheral neuropathy pain. 
I use it for 42 Cymbalta: My use of Cymbalta is two fold. I use it for depression 
and fibromyalgia pain. 
Spironolactone: I use it for acne. Go figure it works 
Promethazine: I use it for gastroparesis. I also use it for sleep 4 or 5 
times a month 
It helps 
with 
131 Nucynta: It helps with my pain from surgery 
Percocet: it helps with my back pain, better then any drug 
Klonopin: I like this medication it helps with my anxiety. 
It help with 11 OxyContin: it help with muscle spasms 
Neurontin: i had drop foot and much pain. it help with the pain 
along with the 3 epidurals i receiveed in my spine. 
                                               
2 Consumer comments are shown exactly as they appeared on the WebMD site. 
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Pattern Count Example drugs and comments2 
Cymbalta: i started this medication years ago. not only did it help 
my depression, it help with my auto immune, muscle and nerve 
pain. 
I take it 1,161 Nucynta: I take it for severe headache and neck pain from arthritis, 
bulging disks, and bone spur in my neck (cervical spine) 
Methadone: I take it for chronic pain it helps a lot 
Flexeril: I take it for muscle spasms related to fibromyalgia. 
I take it for 91 Methadone: I take it for chronic pain it helps a lot 
Methadone: I take it for degenertive disk deteration in my neck. 
Hydrocodone-acetaminophen: i take it for my scholiosis of my 
back 
It works for 258 Methocarbamol: It works for my muscle tension, but gives me a 
headache. 
Diazepam: it works for my pain weal good 
Tramadol: It works for my Arthritis Pain. 
It is useful 
for 
0 … 
Useful for 18 Methadone: very useful for chronic and severe pain associated with 
fibromyalgia/rheumatoid arthritis. 
Effexor: I have been reading the reviews of this med. I have been 
using it for 1.5 yrs and has been very useful for my depression. 
Ultram: this med has been very useful for my hip and back pain. 
Prescribed 
for 
319 Percocet: I was prescribed for kidney stones. definately took the 
pain away and very high. 
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Pattern Count Example drugs and comments2 
Zoloft: I feel like the antidepressant is used in conjunction with my 
cymbalta which I am prescribed for both depression and 
fibromayalgia. 
Celebrex: I was prescribed for knee pain following surgery for torn 
muniscus. 
 
Table 5 shows the frequency of the patterns after removing the comments that referred to only 
known side effects or indications.  
 
Table 5: Frequency of common textual patterns after removing known indications and adverse drug effects. 
Pattern Count Example drugs and comments3 
I use * for 171 Flector: it’s not so bad. I use them for stress headaches only if I 
have a mild headache 
Hydroxyzine: I use this drug for itching attacks and it works fast 
and effective for me. 
Elavil: I use this medication for restless leg syndrom 
I use it for 23 Promethazine: I use it for gastroparesis.i also use it for sleep 4 or 5 
times a month 
Amitriptyline: I use it for ic 
Seroquel: I m in love with seroquel its amazing! I use it for sleep 
and I wake up refreshed 
It helps 
with 
72 Neurontin: it helps with numbness in my legs and arms 
Neurontin: I was diagnosed with rsd in from a fall on the ice. It 
helps with controlling the pain; 
                                               
3 Consumer comments are shown exactly as they appeared on the WebMD site. 
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Pattern Count Example drugs and comments3 
Seroquel: although it helps with my depression I have gained over 
50lbs 
It help with 6 Oxycontin: it help with muscle spasms 
Hydrocodone-acetaminophen: it is ok I think and it help with my 
back pian. 
Neurontin: I had drop foot and much pain. It help with the pain 
along with the 3 epidurals I receiveed in my spine. 
I take it 729 Methadone: I take it for chronic pain it helps alot 
Pristiq: I take it for depression and ptsd as well as for chronic pain 
from failed cervical fusion. 
Zoloft: I have taken it for three years almost and when I take it my 
depression worsens rather in the summer when I wouldnt take it I 
was the happiest 
I take it for 48 Percocet: I take it for pain after a shoulder surgery and it works 
Buspar: I take it for stress. 
Effexor: I take it for depression. 
It works for 155 Pristiq: I do not think it works for me makes me very consipated 
and I think it makes the back of my legs hurt in the muscle part. 
Metformin: I take it before bed no sideeffect so for taking one 
month hope it works for me yes I am scared 
Flexeril: back problems healed up then came right back. overall it 
works for a little while. 
Useful for 13 Effexor: I have been reading the reviews of this med. I have been 
using it for 1.5 yrs and has been very useful for my depression. 
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Pattern Count Example drugs and comments3 
Hydrocodone-acetaminophen: this med. is useful for short term 
relief of pain. 
Ultram: this med has been very useful for my hip and back pain. 
Prescribed 
for 
0 … 
 
A manual review of the remaining comments identified five drugs with potential for repurposing 
(see Table 6). 
 
Table 6: Example comments suggesting the possibility of drug repositioning. 
Medication Indication Adverse effect Patient comments4 
Methadone Dry cough, drug 
withdrawal 
syndrome, opioid 
type drug 
dependence, and 
pain 
Amenorrhea, 
phlebitis, 
sneezing, 
suffering, 
withdrawn, 
hypomagnesemia, 
urticaria, 
rhinorrhea, fever, 
spasm, … 
I use this for diabetic 
neuopathy. Works well with 
very little side effects. 
Elavil Depression, chronic 
pain, irritable bowel 
syndrome, sleep 
disorders, diabetic 
neuropathy, 
agitation and 
insomnia, and 
migraine 
prophylaxis 
None in SIDER elavil is an old school 
antidepressant that is now 
considered a dirty drug 
because of its undesired side 
effects. one of the 
unintended side effects is to 
relax the skeletal muscle 
tissue. I use elavil off label 
to treat my tmj 
                                               
4 Consumer comments are shown exactly as they appeared on the WebMD site. 
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Medication Indication Adverse effect Patient comments4 
Spironolactone Low-renin 
hypertension, 
hypokalemia, and 
Conn syndrome 
Hyperkalemia, 
amenorrhea, 
urticaria, 
epidermal 
necrolysis, 
anaphylaxis, 
fever, toxic 
epidermal 
necrolysis, 
lethargy, nausea, 
… 
I use it for acne. go figure it 
works 
Strattera Attention-
deficit/hyperactivity 
disorder, alone or in 
combination with 
behavioral 
treatment 
None in SIDER I was prescribed this 
medication for slight adhd 
with off label anxiety help. 
Viibryd Acute episodes of 
major depression 
None in SIDER It even helps my migraines 
somewhat (maybe it will be 
off label in the future for 
migraine prophylaxis) 
 
3.5 Discussion 
3.5.1 Comparison of MetaMap Versus a Dictionary-Based Approach 
MetaMap is a sophisticated tool that uses natural language processing and machine learning 
methods; thus, it is not surprising that it is more accurate than the dictionary-based approach. 
MetaMap, to some extent, addresses some general concerns such as disambiguation, misspelling, 
and word normalization, but none of these is addressed in the dictionary-based approach. For 
example, in the phrase “My stomach and back hurts to sit, lay down, or stand,” the dictionary-
based approach would tag “down” as a disease because of overlap with the “genetic disorder down 
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syndrome.” As Table 2 shows, MetaMap recognized about three times the number of disease 
names as compared to the dictionary-based approach. The main reason for this difference is word 
normalization in MetaMap. The dictionary-based approach is limited by its requirement for exact 
matches—for example, a dictionary that contains only “dizzy” would not detect “dizziness” as a 
relevant word. In contrast, MetaMap uses stemming and lemmatization to normalize words. The 
main advantage of dictionary-based mapping over MetaMap is its speed (the dictionary-based 
approach is considerably faster). 
3.5.2 Using Patient Comments for Drug Repurposing 
The reviews commonly described general disorders such as pain, itching, and headache. This is 
expected because comments usually are not authored by medical experts. We observed that 
patients more often tend to report adverse drug events instead of beneficial effects, as some of the 
previous studies reported a similar trend [44]. For example, in the corpus provided by Leaman et 
al [44], they annotated 157 beneficial effects in 3600 posts, while they found 1260 adverse drug 
events. Nevertheless, some patient comments contain beneficial effects of medication, which 
makes social media a useful resource for drug repurposing. This imbalanced distribution makes 
identifying beneficial effects more difficult, however, especially for training a classifier. Our 
results (see Tables 4, 5, and 6) suggest that an effective approach for this task would be to recognize 
the textual patterns that people used to report beneficial effects (eg, “I use [drug] for [disease]”). 
For example, in a review of Viibryd, a user mentioned, “It even helps my migraines somewhat,” 
clearly noting a beneficial effect of the drug, which could be captured by our rule-based system. 
Similar to other computational drug repurposing approaches, these findings need to be reviewed 
manually by experts and then confirmed or rejected by laboratory tests or clinical trials.  
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3.6 Limitations 
There are some known limitations to this study. Analysis of the patient comments, which are 
written in an informal manner, obviously needs a system that can handle spelling and grammatical 
errors. The current implementation does not address these issues. 
Our system covered only simple textual patterns, although the examples in Tables 4 and 5 highlight 
the need to decode complex patterns. A simple pattern-matching system obviously is insufficient 
for a statement such as “I use it for nose allergies and it does not clear up my nostrils.” A system 
should be able to handle negation and coreference. 
Another limitation of this study was that comments originated from only one forum. Other social 
media sites such as Yahoo! Answers, PatientsLikeMe [96], and even Twitter have similar 
information, which could be studied. In addition, using only one resource for known side effects 
and one for indication was another limitation. In Table 3, there are several known indications and 
adverse drug events, which highlight this limitation. 
In this study, we were not able to evaluate our system using measures such as precision or recall 
because of the lack of an annotated corpus.  
3.7 Summary 
We assessed the feasibility of using social media to identify drug-repurposing candidates. After 
collecting patient reviews of medications from WebMD, we compared dictionary-based and 
MetaMap approaches to identify disorders mentioned in the reviews. Reviews describing known 
indications or known adverse drug events were excluded, and the remaining reviews were searched 
for textual patterns commonly used to report beneficial effects. Although the most commonly 
reported disorders were nonspecific (eg, pain, itching, headache), we nevertheless showed that 
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consumer comments contain beneficial effects of medication and have the potential to be used for 
drug repurposing. Our textual patterns were able to capture some beneficial effects, but there is a 
need for a more complex and sophisticated system to identify complex mentions of beneficial 
effects in social media, such as those involving negation or co-reference. 
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Chapter 4: Prioritizing potential drug 
repositioning candidates extracted from 
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4.1 Introduction 
In this chapter, we discuss literature-based discovery (LBD) and how to prioritize potential drug 
repositioning candidates generated by LBD. This chapter consists of three separate studies. In the 
first one, we study the effect of discourse-level and sentence-level analysis for relation extraction, 
which is one of the main components in LBD systems. In the second and third studies, we propose 
and evaluate two prioritizing algorithms to rank potential drug repositioning candidates generated 
by LBD. 
4.1.1 Discourse-level vs Sentence-level analysis for Relation Extraction 
Information extraction (IE) aims to automatically extract information from text. To understand and 
extract information from text, IE systems should look at the text as a whole and not just individual 
sentences. Researchers in the discourse domain agree that usually sentences/clauses are not 
understood in isolation [97]. IE researchers have studied discourse-level analysis [98] for 
applications such as question answering and dialogue generation. One important aspect of 
discourse-level analysis is identifying relation between sentences (clauses), called discourse 
relations, such as contrast or explanation-evidence [97].  
Two main tasks in IE are named entity recognition (NER) and relation extraction. In relation 
extraction, IE systems identify the relation between two or more entities where the entities could 
span multiple sentences. Identifying relations that span multiple sentences needs discourse-level 
analysis to interpret context dependent aspects of meaning such as coreference resolution. 
The goal of the first study in this chapter is to assess the need for discourse-level analysis for 
relation extraction and evaluate the amount of information that IE systems would miss if they just 
focus on the sentence level. To perform this experiment, firstly, Semantic Medline [78] is used to 
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generate a list of potential drug-disease repositioning candidates. Then, we used Medline abstracts 
to find evidence of these drug-disease co-occurrences, using two methods, one based on sentences 
and the second based on discourse-level information.  
4.1.2 Prioritization of LBD generated candidates 
Once the potential novel findings are discovered by LBD systems, it is necessary to eliminate the 
false positives, and identify only true findings (novel discoveries). Distinguishing novel 
discoveries from the others is not a trivial task. Typically, the LBD method consists of two steps: 
1) extracting and mining relations from the text, and 2) eliminating the false positives and 
identifying only the true relations. As a final step, however, it is also important to have a rigorous 
validation of the candidate relations before we proceeding to laboratory or clinical investigations, 
since these are not only expensive but also time consuming. The effectiveness of a LBD system, 
therefore, lies in its rigorous validation. Most prior studies lack such vigorous validation, including 
ranking of the generated candidates generated through LBD process. Though there are a few prior 
attempts [63], [71] in this direction, this area has been largely underexplored. 
In the second part of the study, first we propose and evaluate the effectiveness of two predicate-
based ranking methods for prioritizing potential drug repositioning candidates generated by LBD. 
Then we propose a prioritization method based on context. 
We discuss the methods and results of each study separately. 
4.2 Methods for Generating Candidates from single or multiple sentences 
The study contains two steps: 1) generating a list of drug-disease pairs based on LBDs and 2) using 
the discoveries to evaluate the drug-disease relation extraction by comparing the extractions from 
a single sentence to those from multiple sentences. 
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4.2.1 Generating drug-disease pairs 
In the first step, a list of potential relations between drugs and diseases is generated following 
Swanson’s model [48]. As discussed in Chapter 2, according to Swanson’s model if one scientific 
study notes a correlation between concept A (Starting concept) and concept B (Linking concept), 
and another study mentions a correlation between concept B and concept C (Target concept), then 
there might be a correlation between concept A and C. In our study, drug is the starting concept 
and disease is the target concept, a type of gene serves as a conceptual link between the two.  
We use semantic predications from SemMedDB as a source of these two types of links [75]. For 
example, from the following two predications: 
Flecainide (Drug)     INTERACTS WITH     SCN5A (Gene) 
SCN5A (Gene)        ASSOCIATED WITH     Heart Failure (Disease) 
the system generates Flecainide-Heart Failure as a potential new drug-disease pair. Figure 3 
shows the architecture of the overall LBD process. 
 
Figure 3: Architecture of our LBD system. In this system, starting concept is a drug, the linking concept is gene, and the target is 
a disease that leads to drug-disease discoveries. Our system uses Semantic predications as evidence of correlation between the 
concepts. 
There are two major reasons for our choice of using semantic predication to generate LBDs  
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1) semantic predication takes biological meaning into consideration  
2) the semantic type of the interaction and the contextual information about the interaction 
allow us to filter unnecessary predications such as: NEGATIVE TREATS, NEGATIVE 
ASSOCIATED WITH, etc.  
To further refine the drug-disease pairs to be relevant for LBD, we used Timeline profiles to 
narrow down the drug-disease pairs. Any potential drug-disease pair that occurs before either the 
first occurrence of either the related drug-gene or gene-disease pair is excluded. Equation (1) 
clarifies this use of a Timeline profile: 
               (Eq 1) 
 
where Ysp(Drug-Gene) indicates the publications’ date of all Medline abstracts that contain at least 
one semantic predication between Drug-Gene. For Drug-Disease pairs, we considered publications 
that contain at least one co-occurrence of the entities (Yc). For example, assume four studies in 
2002, 2004, 2007, and 2014 reported association between Drug A and Gene B; and two studies in 
2007 and 2010 mentioned association between Gene B and Disease C. The left-hand side of 
equation would be: 
Max (Min (2002, 2004, 2007, 2014), Min (2007, 2010)) = 20067 
So, if Drug A and Disease C appeared together in any publication before 2007, we do not consider 
Drug A-Disease C. Figure 4 illustrates this example. 
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Figure 4: Timeline profile. This figure illustrates the timeline profile which we used to make the generated drug-disease pairs 
relevant to LBD. In this example, as drug-disease pair co-occurred in 2008 (for the first time), which is after both drug-gene and 
gene-disease relations mentioned in literature, is an acceptable pair in our study. 
 
4.2.2 Evaluating sentence and discourse-level relation extraction 
In the next step, we search Medline abstracts for any co-occurrence (evidence) of drug and disease 
pairs that were not filtered because of their place on the timeline. We categorize the drug-disease 
pairs with at least one evidence in Medline into two groups, depending on whether they occur in 
the same sentence or spanning multiple sentences  
In order to assess the true validity of the drug-disease pairs, we compare the drug-disease pairs 
identified by the system against the chemical-disease associations in the Comparative 
Toxicogenomic Database (CTD) [99], a manually curated database of biological relations and 
associated PubMed citations. A pair is considered valid only if the Medline abstract matches a 
PubMed citation that contains the drug-disease pair.  
Lastly, we perform an analysis to study whether discourse-level analysis would have a positive 
impact on the time lag since the reporting of causal pairs (drug-gene/gene-disease) and the 
appearance of drug-disease pair in the scientific literature. 
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4.2.3 Results 
4.2.3.1 Retrieval of LBD relations 
There were a total of 1,710 approved drugs extracted from DrugBank [93]. Using this list of drugs, 
from SemMedDB there were 4,096 unique drug-gene (A-B) pairs given the gene-related semantic 
predicates extracted from SemMedDB. For all the genes mentioned in A-B pairs we retrieved 
2,741 gene-disease (B-C) relations from SemMedDB. With gene being the common link between 
Drug-Gene and Gene-Disease, we inferred 71,842 potential drug-disease (A-C) relations. The 
results of the study are illustrated in Figure 5. 
4.2.3.2 Comparison of sentence level and discourse level 
We found only 37,719 (52.05%) of the 71,842 drug-disease pairs with at least one literature 
evidence. 
Timeline analysis (Eq1) further narrowed down the number of drug-disease pairs to 8,772 
(23.25%) from 37,719. 6,450 drug-disease relation pairs (73.52%) out of 8,772 identified earlier 
transcend sentence boundaries, demanding the requirement of discourse-level analysis for textual 
extractions.  
For the 2,322 pairs that co-occurred in at least one abstract at the sentence level, we found 89,805 
total co-occurrences in the literature. Further composite analysis revealed that there was far more 
literature evidence across sentences than from a single sentence as shown in Figure 6.  
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Figure 5: Results of the study. 
 
For the 8,322 drug-disease pairs, only 537 (6.4%) of them matched the gold standard, CTD. Further 
analysis revealed that only 130 (24.20%) of the 537 that matched the gold standard occurred in a 
single sentence while the rest (75.80%) appeared across different sentences. Ignoring the match, 
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found in the literature citations we found 17,094 of the drug-disease pairs matched those in the 
CTD. 
 
Figure 6: Comparison of frequencies of drug-disease relations’ co-occurrence in a single sentence versus multiple 
sentences 
 
4.2.3.3 Discourse-level analysis may impact Time lag of LBD 
Figure 7 plots the cumulative percentage which represents a cluster of drug-disease pairs observed 
at a time zone at both the sentence level and discourse level. The trend shows that performing 
discourse-level analysis would significantly advance the identification of the drug candidate for a 
specific disease.  
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4.2.4 Discussion 
In this study, we assessed a method for finding potential drug candidates based on co-occurrence 
of drug-gene pairs and gene-disease pairs within Medline Abstracts. The study also compared the 
candidates found when considering relations found within a single sentence versus those spanning 
multiple sentences and thus require some discourse-level analysis. We found that drug-gene and 
gene-disease relations quite often transcend clausal and sentence boundaries and hence demand 
mechanisms to connect information across such boundaries. Here we found the description of 
23,268 potential drug-disease relations across sentence boundaries versus the 14,451 relations 
within sentences.  
Across all experiments, we observed a consistent trend that drug-disease relations that occurred 
across sentences outnumbered the ones within sentences. Our evaluation against the curated CTD 
resource also reinforces this trend. The study also revealed that a discourse-level analysis would 
have significantly reduced the time lag between the scientific reporting of causal pairs (drug-
gene/gene-disease) and drug-disease relational pair. This shows the need for advance discourse-
level analysis approaches to extract information from literature in time and its ability to hasten the 
pace of discovery. 
Another significant observation is the amount of potential false-positive drug-disease relations 
identified through literature mining. We observe a substantial reduction in the number of drug-
disease relations when we compare the literature-based drug-disease pairs with those from curated 
resource CTD (Figure 5). The reduction among the discourse-level pairs is far greater (3.3 times) 
when compared to the ones from sentence level (2.5 times), which might reflect that the discourse 
level analysis provided more candidates. 
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Figure 7: Comparing the time gap between the first co-occurrence of discovery and the causal pairs (Sentence level 
versus discourse level) 
 
4.2.5 Summary 
In this study, we investigated the extent of the need of discourse-level analysis for drug-disease 
relation extraction from biomedical literature. We used Semantic Medline to extract LBDs and 
then based on co-occurrence analysis, we collected any evidence of the discoveries in Medline 
abstracts. We categorized the evidence into two categories, sentence level and discourse level. 
From subsequent analysis, we infer that there is a potential to miss more than 70% of drug-disease 
relations when we extract information from just the sentence level. This clearly demonstrates the 
need for deeper discourse-level analysis, which may translate to significant improvement in the 
state of the art of NLP techniques. 
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4.3 Prioritization of potential discoveries generated by LBD 
In the second part of this chapter, we study prioritizing drug repositioning candidates generated by 
LBD systems. We propose and evaluate two prioritization approaches; 1) predicate-based 2) 
context-based. 
4.3.1 Predicate-based prioritization 
In this study, we follow the same approach as in the previous study to build a LBD system which 
generates a list of potential drug-disease relations using semantic predications in SemMedDB. 
From the initial list, we explore a series of methods to eliminate erroneous extraction. We then 
assign a score to the remaining pairs (likelihood of being true drug-disease pair) and rank them. 
First, we remove pairs that were qualified by negated predicates such as “did not inhibit”. We also 
remove pairs that were qualified by “co-exists” predicate, which does not semantically define a 
relationship between the pairs. For ranking, we use the occurrence of predicates that qualify the 
binary relationships (between drug-gene and gene-disease) as a feature to rank the final drug-
disease relationships. For example, to rank this pair, Strepsils - Chagas, inferred from these 
semantic predications:  
• Example 1) Strepsils (Drug), INTERACTS WITH, CA2 (Gene) 
• Example 2) CA2 (Gene), AUGMENTS, Chagas (Disease) 
we use the predicate between drug-gene, “INTERACTS WITH”, and the predicate between gene-
disease, “AUGMENTS”. The semantic predicates of both the drug-gene and gene-disease pairs 
(which we call intermediate predicates) play a determining role in qualifying a drug-disease pair. 
We attempt to find a meaningful co-relation between the predicates, one that qualifies drug-gene 
and gene-disease relationships, and the likelihood of generating a true drug-disease pair. The 
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importance of predicate to determine the relevance of drug-disease relations is even more 
important given the fact that the individual semantic predication can occur in more than one 
document. In order to assert a relationship that is inferred from two relationships from multiple 
documents, we propose that the predicate co-relation between the two relationships is one of the 
key factors. Besides, the relation and the predicates may have many-to-many relationships 
meaning that more than one predicate can qualify a relation between the two entities. For example, 
there is only one citation for the relationship between Strepsils and CA2 (example 1), while there 
are six citations that contain the relationship between CA2 and Chagas (example 2). Out of these 
six, three of them are “ASSOCIATED WITH”, two of them are “AUGMENTS”, and one is 
“AFFECTS” relationship. 
To assign a score to each predicate, we take advantage of the existing curated resources. There are 
numerous resources such as the UMLS and the Comparative Toxicogenomics Database (CTD) 
[99], which catalog drug-disease relationships. In this study, we use UMLS as the gold standard 
to evaluate the effect of intermediate predicates in generating a true drug-disease pair. To identify 
already known drug-disease relations in the list generated by the LBD system, we cross-reference 
the generated list of drug-disease pairs with UMLS drug-disease relations. We assign a score to 
each predicate based on how many times they generate a true drug-disease pair. 
We propose two different ranking approaches based on two assumptions. In the first approach, we 
consider the predicate of drug-gene and gene-disease to be independent of each other, while in the 
second we consider the dependencies between the predicates of the two pairs.  
4.3.1.1 Method of ranking based on predicate independence 
Figure 8 shows the steps of calculating the independence scores for each drug-disease pair. In the 
first step, we use SemMedDB to retrieve drug-gene and gene-disease pairs and create a list of 
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potential drug-disease pairs. Then we cross-reference the drug-disease pairs with true drug-disease 
relations in UMLS. As our goal is to identify potential drug-repositioning candidates, we only 
consider drug-disease relations in UMLS where their type is “May_be_treated_by”. As 
SemMedDB stores Concept Unique Identifier (CUI), assigned by UMLS to each biomedical 
entity, we use CUIs to cross-reference our list and UMLS. After identifying true drug-disease pairs 
in our list, we go back to identify drug-gene and gene-disease pairs which created those drug-
disease pairs. Then we count how many times each intermediate predicate contributed to 
generating true drug-disease relations. 
The score for a given drug-disease pair inferred from the individual pair (drug-gene (DG) and 
gene-disease (GD)) is calculated as per the equation 1. 
𝑆𝑐𝑜𝑟𝑒 ='log +𝑃-./012𝑃-./0324 +'log +𝑃-/.016𝑃-/.0364789:;<9: 								(1) 
Where: 
n: the number of semantic predications between the drug-gene extracted from the literature 
m: the same number for the gene-disease relationship 
PpDG-U5: Percentage frequency of the predicates in drug-gene which participated in creating 
drug-disease pairs appeared in UMLS 
PpGD-U: Percentage frequency of the predicates in gene-disease which participated in 
creating drug-disease pairs appeared in UMLS 
PpDG-S6: Percentage frequency of drug-gene predicates in SemMedDB 
                                               
5 The first “P” stands for percentage and the second one stands for predicate and “DG” stands for “Drug-Gene”. 
6 In this notation, “S” stands for “SemMedDB”. 
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PpGD-S: Percentage frequency of gene-disease predicates in SemMedDB 
We use (PpDG-S) and gene-disease (PpGD-S) to normalize the percentage frequencies (PpDG-U and 
PpDG-S). 
 
 
Figure 8: Steps of calculating independence scores 
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For example, consider the above drug-disease pair (Strepsils - Chagas). In order to calculate the 
score for the pair, we add the ratio of log scores of the individual predicates as outlined in equation 
(1). For this example, we add the score of the only predicate, “INTERACTS WITH” that defines 
the relationship between the drug-gene pair (Example 1) with the score of all six predicates 
between the gene-disease pair (Example 2). As mentioned before, more than one predicate may 
qualify a drug-gene/gene-disease pair, which we consider the summation of the ratio of log scores 
of all of them. At this point, we do not consider the semantic relatedness of the predicates while 
calculating their scores. 
4.3.1.2 Method of ranking based on predicate inter-dependence 
In the second ranking, we assume that the predicates of the drug-gene pair and the gene-disease 
pair are dependent on each other while estimating their relevance in pairing a drug with a disease. 
This changes the formula used to compute the final score. Here are the specific steps used to score 
the pairs: 
1) Compute the Percentage Frequency of the combined predicates between the drug-gene 
and gene-disease pair (PpDG-pGD). We limit this calculation to only those drug-disease 
pairs that are represented in UMLS drug-disease relations, which we indicate with this 
notation (PpDG-pGD-U). For this computation, we count how many times each combined 
predicate appeared in true drug-disease pairs (generated by the LBD) and then calculate 
percentage frequency for them. 
2) To normalize the percentages, we use the percentage frequency of the combined 
predicates from SemMedDB (PpDG-pGD-S) as outlined in the following equation:  
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𝑃-./0-/.03 = #𝑝./ ∗ #𝑝/.∑ E#𝑝./2 ∗ #𝑝/.6F;,7<9:89: 																(2) 
where n and m present the number of all different predicates between drug-gene 
and gene-disease, respectively. #𝑝./  shows the frequency of the drug-gene 
predicate in SemMedDB, and #𝑝/.  shows the frequency of gene-disease.  
3) Using the percentage frequency, we calculate the raw score for a given generated drug-
disease pair as given in the following equation (3). 
𝑆𝑐𝑜𝑟𝑒 ='log+𝑃-./0-/.012𝑃-./0-/.032 4;<9: 																			(3) 
where n presents the number of combinations which generate that drug-disease pair 
which is equal to the product of the number of different predicates between the 
drug-gene pair and the number of predicates between the gene-disease pair. 
4.3.1.3 Validation and evaluation 
To validate our ranking methods, we use two resources, CTD and Medline citations. After the 
scoring, the drug-disease pairs are sorted according to the scores, with the highest scoring pairs 
first. We then calculate and compare the percentage of high ranked and low ranked pairs that occur 
in the CTD or co-occurred in Medline abstracts.  
We cross-reference the generated drug-disease with CTD and then using a statistical test, calculate 
the correlation between our ranking methods and being a true drug-disease pair (appearing in 
CTD). We also measure the correlation between the score assigned to each generated pair and the 
number of times that the pair co-occurred in Medline abstracts. As the last step of validation, an 
expert reviewed the top 10 ranked drug-disease pairs manually by conducting a web-based search 
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for each of these pairs and reviewed the relevant scientific literature to identify type of relation 
between the pairs. 
4.3.1.4 Result 
All drug-gene and gene-disease semantic predications were retrieved from SemMedDB. There 
were 19,993 drug-gene pairs (12,666 unique) and 59,945 gene-disease pairs (33,489 unique). 
When we applied Swanson’s model to these pairs, it resulted in the generation of 653,108 potential 
drug-disease pairs (245,102 unique). Of the roughly 245,000 possible pairs, we found that about 
0.5% (N=1,204) of the generated pairs appeared in UMLS. These 1,204 pairs were used to 
calculate percentage frequency related to each drug-gene and gene-disease predicate. 
Figure 9 shows the percentage of high and low ranked drug-disease pairs, which co-occurred in 
Medline abstracts, for the both, inter-dependence and independence, methods. In this figure, the 
Y-axis shows the percentage of pairs that co-occurred in Medline and the X-axis shows the number 
of top ranked pairs. Using a T-test, we found that the inter-dependence method (shown in red) was 
significant P value < 2.2e-16. 
 
 
 
Figure 9: Comparison of the percentage of high and low ranked drug-disease pairs co-occurred in Medline abstracts. 
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Figure 10 shows the results of calculating the percentage of appearance of just the high and low 
ranked drug-disease pairs in CTD.  
 
 
Figure 10: Comparison of the percentage of high and low ranked drug-disease pairs appeared in CTD. 
 
 
Table 7 includes the result of our manual investigation of top ten ranked drug-disease pairs. 
Table 7: Top ten ranked drug-disease pairs  
Drug Disease Type Reference 
Omalizumab Asthma Treatment [100] 
Nifedipine Tetanus Treatment Wikipedia 
Nifedipine Ischemia Treatment [101] 
Omalizumab Dermatitis, atopic Treatment [102] 
Nifedipine Heart failure Treatment [103] 
Nifedipine Renal tubular disorder Relation [104] 
Calan Hypertensive disease Treatment Not found 
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Airol Asthma - Not found 
Ezetimibe Coronary heart disease Treatment [105] 
Cyclosporine Asthma Treatment [106] 
 
4.3.1.5 Discussion 
In the prioritization study, we found that the interdependence-based rankings of drug-disease pairs 
(especially the top ranked pairs) identified through LBD were much more likely to be supported 
by published evidence than the pairs ranked using the independent ranking approach. Figure 9 
shows that 82% of the top 100 drug-disease pairs, ranked using inter-dependence approach had 
supporting literature-based evidence. These pairs were found to co-occur within a single abstract 
in Medline. However, there is a noticeable decline in the percentage of pairs as the ranking goes 
below 100. We observed that pairs ranked using independent ranking approach had relatively 
lower co-occurrence evidence in the biomedical literature.  
We observed a similar trend when we evaluated the confidence levels of the top ranked pairs 
identified using both approaches against the CTD. Figure 10 further confirms the distinct 
advantage of the inter-dependence ranking over the independence ranking. Finally, manual 
evaluation of top ten pairs ranked by inter-dependence approach revealed that the pairs have some 
biological significance based on expert judgment. This indicates that the inter-dependence method 
would be useful for identifying biologically relevant drug-disease pairs. Moreover, nine out of ten 
top ranked drug-disease pairs were found to belong to DRUG-TREATS-DISEASE relationship 
category. 
There are two main limitations in this study. First, we did not have a gold standard of drug-disease 
treatment pairs to evaluate the performance of our approaches. Second, there is an inherent 
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limitation both in the choice of resource (choice of CTD as a resource) and the measure (literature 
co-occurrence) to evaluate the confidence levels of top ranked drug-disease pairs identified by the 
system. CTD though a manually curated resource does not annotate the type of relationship 
between the drug and disease. Hence while evaluating our system against CTD we ignored the 
semantic predications extracted by the system, which would have resulted in loss of valuable 
information. Alternatively, we relied on document level co-occurrence in literature as a measure 
to validate drug-disease relationship. Document level co-occurrence of a relation is not a strong 
indicator for a valid drug-disease relation. There are also limitations in our ranking methods. Using 
some rigorous statistical validation may further refine the notion of semantic predication as 
evidence for relation between biomedical entities for LBD. 
4.3.1.6 Summary 
In this study, we proposed and evaluated two methods for ranking and prioritizing potential drug-
repositioning discoveries extracted from literature. We used drug-gene and gene-disease 
predications, extracted by SemRep, to generate potential drug-disease pairs. The predicates 
between dug-gene and gene-disease pairs are used to rank the generated drug-disease pairs. Our 
results showed using combination of drug-gene and gene-disease predicates can be a metric to rank 
more likely true drug-repositioning candidates higher in the list. 
4.3.2 Context-based prioritization 
In the second study related to prioritization, we propose a new method, called context-based 
prioritization. This method utilizes text surrounding A-B and B-C relations (causal 
associations/findings), to prioritize discoveries generated by LBD systems.  
 58 
While our previous method (Study 2 in this chapter) looked for evidence in the form of sematic 
predications, in this approach, we explore a ranking method that utilizes text surrounding causal 
findings to train a binary classifier that categorizes drug-disease pairs into the following two 
classes:  
a) Positive class (Likely a true drug repositioning candidate) 
b) Negative class (Unlikely a true candidate) 
The classifier uses two sentences, which drug-gene and gene-disease relations are extracted from, 
to classify generated drug-disease pairs into one of these two classes. 
4.3.2.1 Method of context-based prioritization 
Like the two previous studies in this chapter, we use drug-gene and gene-disease semantic 
predications to generate potential drug-disease pairs. Like previous studies, we follow Swanson’s 
model in our LBD system (more details in section 2.1).  
After generating the list of drug-disease pairs, we search these relations in SemMedDB. We 
consider a drug-disease pair as a positive instance, if there is any semantic predication in 
SemMedDB that shows treat relationship (predicate) between that drug and disease. The rest of 
drug-disease pairs in the list, are considered as negative instances. 
We randomly select 5000 drug-disease pairs (2500 positive and 2500 negative instances). We 
retrieve two sentences from Medline abstracts for each of the pairs:  
a) one sentence which contains the corresponding causal drug-gene pair 
b) one sentence which contains the corresponding causal gene-disease pair 
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To address the possible time gap between appearing causal pairs (drug-gene and gene-disease) and 
evidence of drug-disease pair in literature (discussed in section 2.1), we only select the drug-
disease pairs with causal relationships published before 2009. To generate some of drug-disease 
pairs, more than one gene can play role of linking entity. For those drug-disease pairs, we randomly 
select only one gene.  
In the next step, we use these 5000 pairs and the sentences, corresponding to their causal pairs, to 
train a classifier. 
4.3.2.1.1 Features and learning models 
We generate two separate sets of features for each of causal pair, however they contain similar 
features. For each causal pair and corresponding sentences, the following features, determined 
after some preliminary analysis, are used in the classifier: 
1. Words that appeared at least 10 times in the causal sentences 
2. Bi-grams that appeared at least 5 times in the causal sentences 
3. Tri-grams that appeared at least 5 times in the causal sentences 
4. Predicate between the entities 
To find the optimal learning model, we compare several common models such as: Random Forest, 
Naïve Bayes, Support Vector Machine, Decision tree (J48 algorithm) and Rule-based (JRip 
algorithm). We implement the classifier in Java and use Weka training models [107]. 
4.3.2.1.2 Ranking 
After training, the classifier is used to rank generated drug-disease relations by the LBD system. 
For each drug-disease relation, we take the three following steps: 
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1) Classify all pairs of causal sentences, which might lead to a relation (some drug and 
disease pairs can be inferred by more than one gene and also each drug-gene or 
gene-disease pair can be extracted from more than one sentence) 
2) Count the pairs of causal sentences classified as positive (positive instances) for 
each drug-disease pair 
3) Rank the drug-disease pairs based on number of positive instances (in descending 
order). In case of a tie, the linking term count [90] is used to rank the pairs (in 
descending order).  
As the aim of LBD is to discover novel findings, we only rank potential novel drug-disease 
relations and remove already known relations. We consider a drug-disease relation as already 
known relation, if there is at least one semantic predication that shows relationship between them. 
4.3.2.2 Evaluation 
We evaluate the classifier and the ranking approach separately. 
4.3.2.2.1 Classifier 
To evaluate performance of the classifier and find the best learning model, the common metrics, 
precision, recall, and F-Measure are used. 
 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 	 	𝑇𝑟𝑢𝑒	𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒(𝑇𝑟𝑢𝑒	𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒	𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒) 
 𝑅𝑒𝑐𝑎𝑙𝑙 = 	 	𝑇𝑟𝑢𝑒	𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒(𝑇𝑟𝑢𝑒	𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒	𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒) 
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𝐹 −𝑀𝑒𝑎𝑠𝑢𝑟𝑒 = 2 ∗ (𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑅𝑒𝑐𝑎𝑙𝑙)(𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙)  
 
The classifier is evaluated using 10-fold cross validation. 
4.3.2.2.2 Ranking method 
To evaluate the ranking method, we generate a test dataset containing drug-disease pairs where 
their causal drug-gene and gene-disease pairs appeared after 2009 in the literature. We rank these 
pairs using the classifier and use the ranked list to evaluate our method. Firstly, we study 
distribution of known drug-disease relations (pairs with at least one evidence predication) in the 
list.  
Secondly, we calculate the two following correlations (using a t-test) between actual class labels 
(based on evidence predications in SemMedDB) and the following: 
1) Number of instances classified as positive 
2) Difference of number of instances classified as positive and negative 
Thirdly we compare our ranking method with the LTC [69] method. For this comparison, we rank 
the pairs in the test dataset using both methods and compare the distribution of true pairs in the 
ranked pairs. 
In addition to drug repositioning, we assess our method for two other tasks  
1) identifying novel adverse drug reaction (ADR)  
2) identifying existence of relation between drug and disease (regardless of relation type). 
To train the classifier for identifying ADR, drug-disease pairs augmented with “predisposes”, 
“disrupts”, “complicates”, and “causes” predicts are considered as positive instances and the 
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others as negative. For latter one, we use CTD [99] to label instances as positive or negative, 
instead of using the SemMedDB.  
4.3.2.3 Results 
We retrieved all drug-gene and gene-disease semantic predications from SemMedDB, which 
yielded 19,993 drug-gene and 59,945 gene-disease pairs. Following Swanson’s model, 245,102 
unique potential drug-disease relations were generated. Table 8 shows the performance of the 
classifiers trained using different training models for the drug repositioning task. Table 9 illustrates 
the performance of the classifier for identifying adverse drug events and Table 10 shows the 
classifier performance for identifying the relation between drug and disease, regardless of relation 
types. All these tables show the results of 10-fold cross validation. 
Table 8: The performance of the classifier for drug repositioning task 
Training Model Precision Recall F-Measure 
Random Forest 0.785 0.781 0.782 
Naïve Bayes 0.688 0.685 0.686 
SVM 0.708 0.712 0.709 
J48 0.709 0.714 0.711 
JRip 0.686 0.677 0.681 
 
Our calculation showed that there are strong positive correlations between the actual class label 
and the a) number of positive pairs of causal sentences (p-value = 2.2e-16) and the b) difference 
between the number of positive and negative pairs (p-value = 1.005e-07). 
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Table 9: The performance of the classifier for adverse drug event task 
Training Model Precision Recall F-Measure 
Random Forest 0.8646 0.8600 0.8622 
Naïve Bayes 0.7825 0.7819 0.7821 
SVM 0.7281 0.7123 0.7201 
J48 0.7471 0.7472 0.7471 
JRip 0.7910 0.7562 0.7732 
 
 
Table 10: The performance of the classifier for identifying relation between drug and disease task 
Training Model Precision Recall F-Measure  
Random Forest 0.8357 0.833 0.8343 
Naïve Bayes 0.6895 0.688 0.688 
SVM 0.673 0.681 0.6769 
J48 0.7699 0.7422 0.7557 
JRip 0.6953 0.693 0.6941 
 
Out of 245,102 drug-disease pairs, 6205 pairs met the test dataset criteria. We found out that 180 
pairs in the test dataset were true drug-disease pairs (treatment relationship). Figure 11 shows the 
number of true drug-disease pairs in the ranked test dataset. Each interval shows the number of 
true pairs in that interval.  
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Figure 11: Number of true drug-disease pairs in different intervals of ranked test dataset 
 
We compared true drug-disease pairs in top 100 pairs ranked by LTC and our method. There were 
20 true drug-disease pairs in top 100 pairs ranked by our method and only 13 pairs in the pairs 
ranked by LTC. Figure 12 shows result of this comparison and intersection of true drug-disease 
pairs in top 100 pairs. We observed a similar trend in the top 500 pairs. Our method ranked the 58 
true pairs in the top 500 pairs and LTC ranked 42 true pairs (38 pairs in common). 
4.3.2.4 Discussion 
Table 2, 3, and 4 show the performance of our classifier. The performance reported in Table 8 
confirms that using the surrounding text of drug-gene and gene-disease causal relations can help 
determine the likelihood of being a true drug repositioning candidate for generated drug-disease 
pairs. Using the random forest model, the classifier obtained f-measure of 0.78, which is a 
reasonable performance for a classifier for a task of this complexity. The performance of the 
classifier for two other tasks, identifying adverse drug events and relation detection, also supports 
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the proposed approach. Random forest achieved the highest f-measure among the five learning 
models for those two tasks, 0.86 for adverse drug event (Table 9) and 0.83 for relation detection 
(Table 10). As two different public resources are used as silver standard datasets (SemMedDB and 
CTD) to train and test the classifiers for these tasks, the results demonstrate that the performance 
of the classifier is not dependent on the particular dataset.  
 
 
Figure 12: Comparing true drug-disease pairs in top pairs ranked by (A) our method and (B) LTC. 
 
However, we found strong correlations between the actual class label and both the number of 
positive instances and the difference between the number of positive and negative instances, but 
the correlation between actual class label and earlier is stronger. These results support using the 
number of instances classified as positive in our ranking method.  
After ranking drug-disease pairs in our test dataset, we studied the distribution of true drug 
repositioning pairs in the list and as Figure 11 shows, the top ranked pairs include most of the true 
pairs. We identified 32% (58 out of 181) of the true drug repositioning pairs in the top 8% (500 
out of 6000) of ranked pairs. We plotted this distribution for both our ranking and LTC methods 
in Figure 11. The distributions showed that our approach ranked more true pairs in top of the list 
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comparing to LTC method. The next comparison illustrated intersection between top ranked true 
drug repositioning pairs by both methods. Part 1 in Figure 12 demonstrates that our method was 
able to rank 84% (11 out of 13) of true drug repositioning pairs ranked by LTC in top 100, in its 
own top 100 pairs. This number for top 500 pairs (part 2, Figure 12) was even higher 92% (38 out 
of 42). These two Venn diagrams clearly demonstrate that the majority of true pairs are in common 
between both methods, but our method was able to rank more true pairs in higher ranks of the list.  
There are two main limitations in this study, which first one is the lack of access to a gold standard, 
the same as in the previous study. Another limitation is using a balanced dataset (50% positive and 
50% negative cases) for training the classifiers. At this point, we have not trained/evaluated our 
classifiers using an unbalanced dataset.  
However, the results show that our proposed method can play a role in prioritizing LBD findings, 
but still provide pharmaceutical companies with a long list of potential candidates. As future work, 
we plan to not only prioritize the candidates, but also identify and remove false positive candidates 
from the list. 
4.3.2.5 Summary 
In this study [108], we created and tested a new method to prioritize discoveries identified by our 
LBD system. Our LBD system, which is based on Swanson’s model, uses semantic predications 
as causal findings to hypothesize new findings. To rank the generated hypotheses, we trained a 
binary classifier using information surrounding causal findings in literature. We trained our 
classifier for three different purposes, drug repositioning, adverse drug event, and drug-disease 
relation detection. Our classifier obtained reasonable f-measures for all the tasks (respectively, 
0.78, 0.86, and 0.83). Our results showed that the proposed method performed better than one of 
previous methods in ranking true drug repositioning candidates at the top of the list. 
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Chapter 5: Using biomedical literature and 
clinical trials to prioritize potential 
candidates 
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5.1 Introduction 
In chapter 4, we studied two ranking methods for potential drug repositioning candidates generated 
by LBD systems. In this chapter, we study ranking the candidates generated by information from 
a different source, phenome-wide associations studies (PheWAS). The goal of this chapter is to 
assess this method of using text data in prioritizing non-LBD discoveries. 
PheWAS provide evidence for the association of genetic variants with a wide spectrum of human 
disorders[109]. The PheWAS strategy relies on electronically available phenotypic data collected 
from patient cohorts. PheWAS is similar to a genome-wide association study (GWAS), but 
whereas a GWAS asks “What genetic variants are associated with a disease?”, a PheWAS asks 
“What diseases are associated with a genetic variant?”. PheWAS, similar to GWAS, provides us 
a list of gene-disease associations which we utilize to generate a list of potential discoveries.  
5.1.1 Related works of Phenome-Wide Association Studies 
In 2010, Denny et al. [45] introduced PheWAS and demonstrated an approach to discover gene-
disease associations using genetic data coupled to longitudinal electronic medical records. Later, 
Nature Biotechnology published a study by Denny et al. [110] in which they conducted a 
comprehensive PheWAS on 3,144 single-nucleotide polymorphisms (SNPs) that had been 
previously associated with a variety of phenotypes by GWAS. This PheWAS, like many other 
PheWAS published [109]–[111] used International Classification of Diseases version 9 (ICD9) 
codes extracted from electronic medical record systems in large patient cohorts to define case-
control groups for many phenotypes. In the United States, ICD9 coding is primarily used for billing 
and can have variable effectiveness for describing discrete phenotypes. Regardless, Denny et al. 
[110] demonstrate that for many of the GWAS SNPs, PheWAS was able to rediscover expected 
SNP- disease associations while also identifying novel associations [110]. This suggests that 
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PheWAS results may also provide new opportunities to identify candidates for drug repositioning. 
However, it is also likely that false positives exist in the reported PheWAS data, especially for 
those SNP-disease associations with moderate evidence of association. Independent PheWAS may 
prove highly effective when replicating novel findings. Regardless, to balance accuracy while still 
allowing for discovery and hypothesis generation, one might choose a loose P-value threshold 
from PheWAS data.  
5.1.2 GWAS vs PheWAS in drug repositioning 
As mentioned before, drug repositioning is the process of discovering new indications for existing 
drugs [112]. Critical to drug repositioning is the initial identification of candidate drug-disease 
relationships. Genetic-based association studies, including GWASs, have proven to be effective 
for generating hypotheses related to drug repurposing [113], [114]. GWASs can identify disease 
susceptibility genes that are targets for existing drugs used to treat different conditions. For 
example, a large GWAS implicated flavopiridol, a CDK4 inhibitor and anti-cancer agent, as a 
possible drug to repurpose for the treatment of rheumatoid arthritis [115]. However, GWAS data 
is partly limited by the number of diseases that can be linked to a gene. A unique advantage of the 
PheWAS approach is the ability to measure genetic associations with thousands of diseases 
simultaneously, which may be ideal when identifying pleiotropic effects. As a result, PheWAS 
may prove to be an effective alternative to GWAS when identifying susceptibility loci. 
Importantly, PheWAS may further expand the horizon for discovery and prioritization of 
candidates for drug repositioning [116].  
5.2 Method 
We seek to demonstrate the potential use of PheWAS information for drug repositioning by cross-
referencing PheWAS data with biomedical databases.  
 71 
5.2.1 Generating Candidates 
We begin by extracting all SNP-disease associations from the recently reported PheWAS by 
Denny et al. [110]. We filter the association based on P-value. We use a loose P-value threshold 
(P ≤ 0.05). Only those SNPs that are mapped directly to a gene according to dbSNP, which includes 
2 kb upstream and 500 bp downstream, are considered in the study. In the next step, we retrieve 
all drugs from DrugBank and their direct and indirect gene targets and generate a list of drug-gene 
relations. These drug target data have been previously applied to other in silico drug-screening 
studies [117]–[119]. Then, we look for all sets of transitive pairs, A-B, B-C where A-B is a disease-
gene pair from PheWAS and B-C is a gene-drug pair from DrugBank. (Figure 13). 
 
Figure 13: The three steps in the discovery process. (1) PheWAS associations [108] to connect diseases to genes; (2) DrugBank 
analysis to connect genes to drugs; and (3) drug repurposing targets that connect drugs with diseases. Highlighted is an example 
where this process rediscovered glyburide as an indication to treat type 2 diabetes. 
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5.2.2 Validation and Ranking Candidates 
To measure the relevance of the generated drug-disease pairs identified using PheWAS data under 
a loose P-value cutoff, we assess the co-occurrence of the drug and disease terms in Medline 
abstracts. For this purpose, MetaMap [95], is used to extract disease names from the PheWAS 
phenotypes and then we scan Medline abstracts for the paired drug-disease terms using a text 
search engine, Apache Lucene. 
To validate our method, we generate a list of drug-disease pairs (the same number of pairs as our 
method generated) where both drug and disease names are randomly selected from a list of drugs 
and diseases. Then we follow the same approach to identify any co-occurrence of these pairs in 
biomedical literature. Finally, we compare the percentage of the pairs in both lists which have at 
least one co-occurrence in literature. We repeat the process 1000 times and look for any significant 
difference in the percentages. 
For comparison purposes, the process is also performed using gene-disease pairs driven solely by 
GWAS data extracted directly from the GWAS catalog [120]. 
To assess the novelty of the drug-disease pairs and to better rank candidates for drug repositioning, 
we further cross-reference all pairs with the clinical trial registry (clinicaltrials.gov). We categorize 
the pairs into four categories, including: 
• known/rediscovered 
• strongly supported (some support in the literature and clinical trial registry) 
• likely (some support in the literature or clinical trial registry) 
• novel (no evidence in the databases) 
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5.3 Result 
We extracted all 212,851 SNP-disease associations from PheWAS catalog [110]. Only 1,501 SNPs 
were mapped directly to a gene according to dbSNP, which allowed us to identify 48,488 unique 
gene-disease relationships. Using gene-drug relations in DrugBank, we were able to identify 
52,966 drug-disease pairs.  
Of the 52,966 drug-disease pairs, 14,816 (28%) were supported in the literature. After permuting 
drug-disease pairs 1,000 times and cross-referencing random drug-disease pairs with Medline 
abstracts, we identified a total of 3,270 ± 57 drug-disease pairs (6.2%; Figure 14-a) that co-
occurred in literature, which suggests that PheWAS data significantly enriches information for 
drug-disease pairs supported by evidence. Of the 52,966 drug-disease pairs, 127 pairs were 
‘rediscovered’ according to original indications listed in DrugBank (Table 11). As an example, the 
PheWAS catalog reported an association between SNP rs2515629 and ‘type 2 diabetes’ (P = 
0.000732). A search of dbSNP maps rs2515629 to the gene ABCA1, which is mentioned in 
DrugBank as a gene target for glyburide, a drug used to treat type 2 diabetes. Therefore, this 
process appropriately identified type 2 diabetes as an indication for glyburide (Figure 13). By 
contrast, using the GWAS approach, the number of drug-disease pairs identified was 7,945 of 
which 3,087 (38.8%) co-occurred in at least one abstract (Table 11). When the same permutation 
procedure was established for the GWAS data, a total of 489 ± 21 pairs (6.2%) appeared at least 
once in the abstracts (Figure 14-b).  
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Figure 14: Co-occurrence distribution plotted for 1000 randomly permuted drug-disease pairs identified in 
Medline Abstracts for (A) PheWAS- and (B) GWAS-derived data. For each dataset, the number observed drug-
disease pairs with evidence in Medline Abstracts is also highlighted. This contrast demonstrates that there is a 
significant difference between the observed drug-disease pairs in Medline Abstracts from those randomly 
permuted. 
 
The resulting distribution of the 52,966 PheWAS-derived pairs and 7,945 GWAS-derived pairs 
into the four categories of discovery, are shown in Table 11. 
Table 11: Comparison of PheWAS- and GWAS-based approaches to drug repositioning 
 
 GWAS PheWAS 
Drug-Disease pairs 7945 52,966 
Drug indication type   
Known/rediscovered 140 (1.8%) 127 (0.2%) 
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Strongly supported 908 (11.4%) 2,583 (4.9%) 
Likely 2,060 (25.9%) 12,221 (23.1%) 
Novel (candidates for drug repositioning) 4,837 (60.9%) 38,035 (71.8%) 
 
Some examples from each category driven by PheWAS data are illustrated in Table 12. For 
example, PheWAS results indicate that SNP rs2736100 in the gene TERT is associated with 
diabetes (P = 0.00029). Zidovudine, a drug prescribed to treat HIV/AIDS, is a reverse transcriptase 
inhibitor and may inhibit TERT activity. This example suggests that zidovudine might be 
repositioned to treat diabetes, a not unreasonable assertion as increased telomerase activity has 
been reported to be associated with increased diabetes complications [121]. It should be noted that 
the co-occurrence of drug-disease pairs may also be the result of adverse drug events [122].  
Table 12: Examples of Drug-Disease pairs identified from PheWAS data 
Status Drug Disease Indication 
PheWAS 
SNP 
PheWAS 
P-value 
Associated 
Gene 
Medline 
Citations/ 
Clinical Trial 
Citations 
(count) 
Known Paclitaxel breast cancer rs242557 0.041 MAPT 3003/321 
Known Glyburide type II diabetes rs2515629 0.00073 ABCA1 240/12 
Strongly 
supported 
Dexametha
sone 
rheumatoid 
arthritis rs4795067 0.050 NOS2 4271/48 
Strongly 
supported Everolimus breast cancer rs17036350 0.040 MTOR 221/46 
Likely Verapamil vaginal cancer rs216013 0.011 CACNA1C 1144/0 
Likely Chlorpromazine liver cancer rs11214606 0.033 ARVCF 423/0 
Novel Porfimer hyper-cholesterolemia rs6511720 2.5E-6 LDLR 0/0 
Novel Zidovudine diabetes rs2736100 0.00029 TERT 0/0 
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5.4 Discussion 
This study offers many promising new candidates to explore. Complete results from this study are 
available to the scientific community for further experimental validation and clinical study [22], 
[23]. For example, an investigator interested in developing a new drug for breast cancer would 
have 18 candidates, including oxcarbazepine and disopyramide, for investigation. Similarly, new 
indications may be identified for existing medications. On the basis of our analysis, docetaxel has 
88 potential new indications, including psoriasis, migraine and osteoporosis.  
Because the SNPs selected for the PheWAS were derived from reported GWAS, it is not surprising 
that several drug-disease pairs identified by PheWAS overlap those identified by GWAS. 
Specifically, there were 161 overlapping drug-disease pairs between GWAS and PheWAS data; 
70 were initially identified as ‘novel’ (no evidence in the databases). The 161 overlapping pairs 
may be an under- representation of the true overlap as phenotypic terms used by the GWAS may 
differ from those defined by the PheWAS, especially GWAS that assessed quantitative traits. For 
example, the PheWAS identified a link between LDLR, a target for Porfimer [93], and “hyper-
cholesterolemia,” whereas GWAS connected LDLR to “cholesterol” (Table 11).  
As mentioned previously, we chose a loose P-value threshold for PheWAS data for discovery and 
hypothesis generation. On the basis of permutation analysis, many of these associations may be 
real, but these are undoubtedly mixed with false positives. We investigated 
the effect of various P-value thresholds. When using a P-value threshold of ≤ 0.001, approximately 
250 drug-disease pairs with evidence were observed. This more stringent P-value threshold may 
decrease false positives but also dramatically reduce the number of potential candidates. 
Interestingly, as P values decreased below 1.0 × 10–5, the proportion of drug-disease pairs with 
evidence in the literature increased (Figure 15). Additional replication of PheWAS findings should 
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improve the association results. Furthermore, incorporating other biomedical databases, such as 
SemMedDB [78] and the Drug-Gene Interaction Database [123], in combination with manual 
curation, may also significantly benefit the prioritization process.  
 
Figure 15: Number of drug-disease pairs by P-value threshold for those pairs with and without evidence according to Medline 
Abstracts, Clinical Trial Registry, or DrugBank. 
 
Even with many drug-disease pairs identified through this raw screen, other factors of course 
influence whether candidates for drug repurposing may be suitable for commercial development. 
Economic factors may limit some drug candidates. Pharmaceutical companies may not support 
drug repositioning due to insufficient market potential driven by disease frequencies, competing 
medications, and/or intellectual property protection. In addition to economic constraints, some 
agents may require reformulation due to therapeutic index, toxicity profile and/or agent type 
(topical agents versus systemic agents). A second level ‘screen-out’ approach would further help 
identify candidates for repositioning. 
 78 
5.5 Summary 
The conclusions of this study are two-fold. First, we suggest that the utilization of PheWAS data 
provides a robust approach for identifying new drug candidates for repurposing. Second, we 
illustrate how to use biomedical literature and clinical trials to rank non-LBD drug repositioning 
candidates. In this study, we identified nearly 14,800 drug-disease pairs with some evidence of 
support in biomedical literature or clinical trials. In addition, we identified more than 38,000 novel 
candidates for re-purposing, encompassing hundreds of different disease states and over 1,000 
individual medications. We anticipate that these results will be highly useful for hypothesis 
generation in the field of drug repurposing.  
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Chapter 6: Conclusion 
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6.1 Introduction 
The drug development process is a prolonged and expensive process. In this thesis, we examined 
drug repositioning as a popular alternative approach to reducing the cost and time needed for 
developing a new drug. We explored the opportunity of identifying potential drug repositioning 
candidates by leveraging publicly available text-based resources. We conducted five studies and 
utilized reviews posted by patients to WebMD, abstracts from the biomedical literature, clinical 
trials, and PheWAS data as the main resources for generating and prioritizing the potential drug 
repositioning candidates. We developed a rule-based system and studied the feasibility of using 
patient reviews in drug repositioning. To our knowledge, this is the first study to consider using 
social media data for this purpose. We were able to detect several beneficial effects of medications 
reported by patients, which highlighted the value of social media in drug repositioning.  
In three studies, we focused on literature-based discovery. First, we presented a method to compare 
the relative importance of using either isolated sentences or multiple sentences comprising a 
discourse to identify potential candidates. We found that nearly three quarters of the findable 
candidates would require mining candidates using multiple sentences. In the other two studies, we 
proposed statistical methods to prioritize the potential candidates. In the first method, we utilized 
predicates in semantic predications extracted from Medline abstracts to rank the candidates. Our 
results illustrated that predicates can be a metric to rank more likely true drug-repositioning 
candidates higher in the list, however this approach is limited to LBD systems that utilize semantic 
predication for discovery. The other method utilized the text surrounding discoveries to train 
several classifiers and used the classifiers to score and rank the potential candidates. Our analysis 
showed the effectiveness of this method as well. These two studies illustrated that by using 
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computational methods and existing knowledge sources, we can rank and narrow down the long 
lists of the potential candidates generated by LBD systems. 
In the fifth study, we utilized text data to prioritize and categorize potential drug repositioning 
candidates generated by a non-LBD system. In this study, we used Phenome-Wide Association 
Studies to generate a list of potential candidates and then utilized text from the biomedical 
literature and clinical trials to categorize and prioritize the candidates. The results of this study 
showed that PheWAS can be used to generate new hypotheses for drug repositioning and that 
biomedical literature and clinical trials can be used to prioritize the candidates and filter out already 
known candidates. 
6.2 Comparison 
In this section, we will compare the systems presented in this thesis based on the number of 
potential drug repositioning candidates generated by each. We presented three main systems to 
generate the potential candidates: 1) LBD using semantic predication, introduced in chapter 4 2) a 
PheWAS based system, presented in chapter 5 and 3) a GWAS based system, introduced in chapter 
5 as well. Table 13 and figure 16 show the number of potential candidates generated by each 
system, and the percentage of the candidates categorized as known, supported in literature (based 
on co-occurrence of drug and disease), and novel. 
Table 13: Comparing the systems based on the number of generated candidates 
System Total number Already known Supported in literature Novel 
LBD using sematic 
predication 
245,102 1,204 (0.49%) 
(in UMLS) 
53,922 (22%) 189,976 (77.5%) 
PheWAS based 52,966 127 (0.2%) 
(in DrugBank) 
14,816 (28%) 38,035 (71.8%) 
GWAS based 7,945 140 (1.8%) 
(in DrugBank) 
2,963 (37.3%) 4,837 (60.9%) 
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Figure 16: Comparing the systems based on the number of drug repositioning candidates 
By examining the results in Table 13, it is clear that the LBD system generated more potential drug 
repositioning candidates than the others, but it provided the smallest percentage of candidates 
supported by evidence from the literature. The GWAS-based system generated only 7,945 
candidates with 37.3% supported by the literature, which suggests a lower false positive rate, but 
has a limitation of generating the smallest number of novel candidates. Figure 14 indicates that for 
all three systems, the biggest proportion of the candidates are novel and thus there is a need to 
prioritize them and remove false positive candidates.  
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6.3 Future work 
In this thesis, we assessed methods for leveraging three important text-based resources, social 
media, biomedical literature, and clinical trials. We did not include one of the most important text-
based resources now available, clinical notes, because they are not public. Exploring clinical notes 
as resource to identify and prioritize the potential candidates is a potentially valuable extension to 
this work, as they might provide the earliest evidence of off-label uses of prescribed medications. 
For each study described here, we mentioned the limitations which could be considered as potential 
future work. For example, for the social media study, as we only explored the feasibility of using 
social media for drug repositioning, and only considered data from one source, many extensions 
are possible such as: exploring the other websites (tweeter, Facebook, …), creating an annotated 
dataset and developing statistical methods, using state-of-the-art NLP algorithms to address known 
issues with consumer-generated text, such as mis-spellings and ungrammaticality. To address the 
need for better methods for prioritizing candidates and removing more false positives, the next 
step would be to explore incorporating other biomedical databases, such as SemMedDB [78] and 
the Drug-Gene Interaction Database [123], in combination with manual curation.  
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